In This Story
Ozempic maker Novo Nordisk (NVO) revealed mixed results today for a stage 2 trial of an speculative weight loss tablet that works inadifferentway than its already-popular weight loss drug Wegovy.
Uber shipment collaboration sendsout Darden Restaurants stock travelling greater
Novo Nordisk stock fell almost 6% throughout Friday earlymorning trading after it published the outcomes.
The Danish pharma giant evaluated monlunabant, a drug it obtained in 2023 with its $1 billion purchase of Inversago Pharma, in a stage 2 trial including 243 individuals with weightproblems and other associated health problems.
Monlunabant works by obstructing CB1 receptors, which are discovered in the brain and anxious system and have an result on hunger. Conversely, Wegovy works by simulating a gut hormonalagent that controls blood sugar levels and lowers cravings.
The brand-new drug was evaluated in once-daily dosages of 10mg, 20mg, and 50mg.
Starting from an average weight of 110.1 kg (242.7 lbs), individuals taking any dosage of monlunabant lost substantially more weight than those on a placebo. After 16 weeks, individuals taking a everyday 10 mg dosage of monlunabant lost an average of 7.1 kg (15.6 lbs), or about 6% of their weight, while the placebo group just lost about 0.7 kg (1.5 lbs). Higher dosages didn’t outcome in much more weight loss beyond that.
In the trial, the most typical side impacts were digestion problems, which were typically moderate to moderate and depended on the dosage. People taking monlunabant likewise reported more mild-to-moderate mood-related side impacts, consistingof stressandanxiety, irritation, and sleep issues, compared to those on a placebo. However, Novo Nordisk reported no serious neuropsychiatric side impacts.
“The stage 2a results show the weight-lowering possible of monlunabant and that additional work is required to determin